Literature DB >> 29144739

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Ian Churcher1.   

Abstract

Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches. In this Perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degradation concepts and their resulting applications to medicine discovery. The approach has the potential to bring disruptive change to drug discovery; the many potential advantages and outstanding challenges which lie ahead of this technology are discussed.

Mesh:

Substances:

Year:  2017        PMID: 29144739     DOI: 10.1021/acs.jmedchem.7b01272

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  90 in total

Review 1.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

2.  A MedChem toolbox for cereblon-directed PROTACs.

Authors:  Christian Steinebach; Izidor Sosič; Stefanie Lindner; Aleša Bricelj; Franziska Kohl; Yuen Lam Dora Ng; Marius Monschke; Karl G Wagner; Jan Krönke; Michael Gütschow
Journal:  Medchemcomm       Date:  2019-05-28       Impact factor: 3.597

3.  PROTAC Molecules for the Treatment of Autoimmune Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

4.  Treatment of Prostate Cancers and Kennedy's Disease by PROTAC-Androgen Receptor Degradation.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-04-01       Impact factor: 4.345

5.  Treatment of Alzheimer's by PROTAC-Tau Protein Degradation.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-03-12       Impact factor: 4.345

Review 6.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

7.  Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling.

Authors:  Inchul You; Emily C Erickson; Katherine A Donovan; Nicholas A Eleuteri; Eric S Fischer; Nathanael S Gray; Alex Toker
Journal:  Cell Chem Biol       Date:  2019-12-16       Impact factor: 8.116

8.  Optical Control of Small Molecule-Induced Protein Degradation.

Authors:  Yuta Naro; Kristie Darrah; Alexander Deiters
Journal:  J Am Chem Soc       Date:  2020-01-23       Impact factor: 15.419

9.  Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation.

Authors:  Tanpreet Kaur; Arya Menon; Amanda L Garner
Journal:  Eur J Med Chem       Date:  2019-01-31       Impact factor: 6.514

Review 10.  Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.

Authors:  Xu Ran; Jason E Gestwicki
Journal:  Curr Opin Chem Biol       Date:  2018-06-13       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.